HORIZON Investigators of the Huntington Disease Study Group and European Huntington's Disease Network*.
A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease.Arch Neurol.
2012 Oct 1;:1-9.
PubMed Abstract